Page 6,247«..1020..6,2466,2476,2486,249..6,2606,270..»

Appeals court allows Cardinal Health to sell controlled substances

Posted: March 6, 2012 at 7:41 pm

By Amy Pavuk, Orlando Sentinel 12:48 p.m. EST, March 6, 2012 A federal appeals court has temporarily stopped the U.S. Drug Enforcement Administration from banning Cardinal Health, a prescription-drug wholesale distributor with a facility in Lakeland, from distributing controlled substances. The ruling is the latest of legal twists in the case against Cardinal, which distributes drugs to more than 2,500 pharmacies in the Southeast. DEA claims in court records that Cardinal Health has a history of problems and violated a memorandum of agreement the company made with the agency. In early February, DEA attempted to suspend Cardinal's license, but the company fought back. Cardinal Health sought a temporary restraining order against DEA, and a judge granted that request Feb. 3. But after hearing arguments in the case, which is being handled in the District of Columbia, a judge dissolved that temporary restraining order. The judge ruled last week that all orders for controlled substances, which include the highly addictive and powerful painkiller oxycodone, must be discontinued. Cardinal Health appealed that decision, and the U.S. Court of Appeals for the District of Columbia Circuit ruled Friday that the DEA's immediate suspension order be stayed pending further order of the court. Read … Continue reading →

Posted in Wholesale Pharmacy | Comments Off on Appeals court allows Cardinal Health to sell controlled substances

Judge jails drugs gang for 18 years

Posted: at 7:40 pm

Last updated at 13:25, Tuesday, 06 March 2012 FOUR men who transported drugs into South Cumbria from Merseyside have been jailed for a total of 18-and-a-half years. Title Author Copyright Description Preston Crown Court yesterday heard how Liverpool dealers Nicholas Flaherty and Kurtis Carney used a Furness address as a safe house for their drugs operation so they could more easily blend in with the local community. One of them used taxis to run around the streets and make deliveries. A dirty phone enabling contact between addicts and dealers was used by 36 Barrow addicts requesting a drugs sale. The pipeline of drugs to Barrow was serviced every four to five days during the period the conspiracy ran. Andrew Millington and Daniel Barclay, both of Barrow, were also convicted for their involvement in the drugs ring. The court was told that when an address in Lindal Street was searched, police discovered a machete under the doormat, a bag of knives in a kitchen cupboard and a shotgun cartridge on a kitchen worktop. See original here: Judge jails drugs gang for 18 years … Continue reading →

Posted in Drugs | Comments Off on Judge jails drugs gang for 18 years

Research and Markets: China Asthmatic Prescription Drugs Sales Data 2006-2010: an essential resource for …

Posted: at 7:40 pm

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/fa2356/china_asthmatic_pr) has announced the addition of the "China Asthmatic Prescription Drugs Sales Data 2006-2010" report to their offering. The series of China Prescription Drug (CPD) sales reports have systemically analyzed Chinese prescription drug market, according to different therapeutic areas. All market estimates of drug utilization in China are based on hospital drug prescription and drug purchasing data from extensive hospital coverage in 16 major cities and more than 300 hospitals. Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions. Market shares from all major manufacturers including multinational and Chinese pharmaceutical companies and key products are analyzed systemically. The comprehensive prescription data in China will present you a clear picture of the competition landscape of Chinese drug market for each therapeutic area (such as cancer, hypertension, diabetes, to name a few) and the market potential for your company's product(s) that already marketed in China or if you are planning to bring your drugs to the China market. This series of China CPD reports have been indispensable references for all levels of decision makers … Continue reading →

Posted in Drugs | Comments Off on Research and Markets: China Asthmatic Prescription Drugs Sales Data 2006-2010: an essential resource for …

Cigna Open To Selling Pharmacy-Benefit Manager Business (Again)

Posted: at 7:40 pm

By Jon Kamp and David Benoit There has been some chatter lately that Cigna could potentially unload its pharmacy-benefit manager business, a move Cigna considered in 2009. Speaking at Cowen health-care conference,CEO David Cordani doesnt definitively say one way or the other, but he does say Cigna will remain open to structural alternatives that maximize shareholder value so long as they continue to enable me to deliver our promise to ourclients and customers. At the same time, he says this is an important business that is well performing based on a variety of measures. In 2009, there was a rash of consolidation discussions in the pharmacy-benefit manager business including Express Scriptss $4.68 billion deal for health-insurer WellPoints in-house pharmacy-benefit manager operations. Medco Health, Aetna and Cigna all talked up expectations. Aetna would eventually sign a contract to outsource its operations to CVS Caremark, but Cigna said it was sticking with its business. Flash forward to 2012 and the industry is again abuzz with consolidation talk as Express Scripts is waiting on regulatory approval for its nearly $30 billion deal for rival Medco Health. As Cigna closed its deal for medicare insurance company HealthSpring, which outsources its own pharmacy-benefits operations to … Continue reading →

Posted in Pharmacy | Comments Off on Cigna Open To Selling Pharmacy-Benefit Manager Business (Again)

CareFusion To Acquire Pharmacy Automation Technology Leader

Posted: at 7:40 pm

SAN DIEGO, March 6, 2012 /PRNewswire/ --CareFusion today announced an agreement to acquire PHACTS, LLC, a Seattle-based technology and consulting company that helps hospital pharmacies better manage inventory, reduce pharmaceutical costs and streamline operations. Terms of the deal were not disclosed. The acquisition will advance CareFusion's strategy to offer hospitals safe and efficient systems to manage medication throughout their facilities from the loading dock to the patient bedside and through to waste segregation. By adding PHACTS to the company's core Pyxis dispensing technologies portfolio, CareFusion will be able to provide health systems better visibility into drug inventories, helping to reduce on-hand inventory, streamline staff workflow, manage drug shortages and improve financial performance. In November 2010, CareFusion announced a global marketing relationship as the exclusive reseller of PHACTS pharmacy inventory management software and automation. Through this partnership, PHACTS expanded its base of customers by 50 percent to more than 200 customers. "With the addition of PHACTS market-leading products to our portfolio, CareFusion is better positioned to help hospitals realize significant savings, including a reduction in medication inventory on-hand levels by up to 40 percent," said Tom Leonard, president of Medical Systems at CareFusion. "The acquisition will enable us to more directly … Continue reading →

Posted in Pharmacy | Comments Off on CareFusion To Acquire Pharmacy Automation Technology Leader

Cord Blood Registry's Leading Science and Research Team – Video

Posted: at 6:09 pm

05-03-2012 11:59 Learn more about cord blood stem cells here http://www.cordblood.com Cord Blood Registry's Scientific and Medical Affairs team, led by Heather Brown Vice President of Scientific and Medical Affairs, is dedicated to helping understand, communicate and advance stem cell medicine. Her team's focus is on helping find new uses for cord blood, including supporting research that is looking for treatments for conditions that have no treatment today. Our company was founded on the belief that saving newborn stem cells can change the future of medicine. Whether it's providing newborn stem cell banking at no cost to a family with a medical need or partnering with world-class researchers for first-of-their-kind clinical trials, we are committed to advancing stem cell medicine and finding new cures. Read the rest here: Cord Blood Registry's Leading Science and Research Team - Video … Continue reading →

Comments Off on Cord Blood Registry's Leading Science and Research Team – Video

Penn Medicine Science Educator Recognized by Society for Developmental Biology

Posted: at 6:09 pm

PHILADELPHIA Jamie Shuda, EdD, director of life science outreach at the University of Pennsylvania's Institute for Regenerative Medicine (IRM), and coordinator of life science education at the Netter Center for Community Partnerships also at Penn, along with Steve Farber, PhD, Investigator, Embryology Department, Carnegie Institution for Science, Baltimore, have been awarded the Hamburger Outstanding Educator Prize from the Society for Developmental Biology (SBD). Shuda and Farber run Project BioEYES, a K-12 science education program that provides classroom-based, hands-on learning using live zebrafish to teach about how cells and animals develop. The program is located within the Perelman School of Medicine, Penn; the Carnegie Institution; Notre Dame University in South Bend, IN; and Monash University in Melbourne, Australia, among others, and reaches over 9,000 students per year. "I am honored that the Society for Developmental Biology has chosen me and Dr. Farber as the 2012 recipients of the Viktor Hamburger prize," says Shuda. "Project BioEYES exemplifies how scientists and educators can come together to teach cutting edge, exciting science to students of all ages. Collaboration across disciplines is greatly supported by Penn and the IRM and it is wonderful that the university is being recognized for their public engagement. Viktor Hamburger … Continue reading →

Comments Off on Penn Medicine Science Educator Recognized by Society for Developmental Biology

Nuvilex Forecasts Vast Partnership Opportunities Using Breakthrough Stem Cell Technology

Posted: at 6:09 pm

SILVER SPRING, Md.--(BUSINESS WIRE)-- Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, today pointed out the potential for substantial partnership and licensing opportunities using the companys cell encapsulation technology for applications in stem cell research and medicine. Migration of implanted cells away from the target site and host rejection have been recognized as fundamental challenges faced by the stem cell community regarding their use in therapy, which the companys technology overcomes. The technology being acquired from associate SG Austria is used to place live stem cells into strong, flexible and permeable capsules. These capsules can then be implanted into animals or humans for specific therapies. Stem cells can then exist at the desired location inside the capsules, prevented from migrating and protected from the immune system that aims to eliminate such foreign cells from the body. Stem cell therapy is being used by clinicians throughout the world for treating such diverse diseases as spinal cord injury, amyotrophic lateral sclerosis, burns, glioma, multiple myeloma, arthritis, heart disease, stroke, Stargardt's Macular Dystrophy, and age-related macular degeneration, among others, most of which can be found at ClinicalTrials.gov. Historically, researchers have faced numerous difficulties in succeeding with certain stem … Continue reading →

Posted in Stem Cell Treatments | Comments Off on Nuvilex Forecasts Vast Partnership Opportunities Using Breakthrough Stem Cell Technology

Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344

Posted: at 6:08 pm

SAN DIEGO, March 6, 2012 /PRNewswire/ --Marshall Edwards, Inc. (Nasdaq: MSHL - News), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical testing for oncology drug candidate ME-344, the Company's lead mitochondrial inhibitor. "I am extremely proud of our clinical operations and pre-clinical research teams in reaching this important milestone, less than seven months since our IND for ME-143 was approved by the FDA to begin clinical testing," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of Marshall Edwards. "We are prepared to initiate a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors immediately following approval by the FDA." Marshall Edwards also announced that it has commenced dosing of the fourth cohort in its Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumors. The Company expects to collect final safety and pharmacokinetic data from this trial by June. "We continue to execute on the clinical development plan we set forth for our two most promising drug candidates," said Robert Mass, M.D., … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344

Medistem Inc. to Add Kidney and Lung Failure to Clinical Trials of Endometrial Regenerative Cells (ERC) Stem Cells in …

Posted: at 6:08 pm

SAN DIEGO, CA and PORTLAND, OR--(Marketwire -03/05/12)- Medistem Inc. (Pinksheets: MEDS.PK - News), in partnership with its Russian licensee, ERCell, announced the signing of a letter of intent* to begin clinical trials using Medistem's Endometrial Regenerative Cells (ERC) stem cells for renal, lung and peripheral artery disease. Trials will be conducted in the S.M. Kirov Military Medical Academy in St. Petersburg, Russia. Under the agreement, Medistem, ERCell and the Academy will work together to a) Design and obtain approval for clinical trials; b) Provide training and execute the trials; and c) Identify opportunities for commercialization of the ERC product through existing military and governmental programs. Under the license agreement, Medistem receives cash and royalty revenues from Russian developmental activities as well as all the data gathered from the trials. According to the agreement, work performed by ERCell will be conducted according to international "Good Clinical Practices" (GCP) so the data gathered can be used for Russian registration as well as to support US FDA submissions. "At Medistem, our philosophy has always been to follow the data. We aim to be as aggressive as possible, to obtain as much data as possible, as quickly as possible," stated Thomas Ichim, CEO of … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Medistem Inc. to Add Kidney and Lung Failure to Clinical Trials of Endometrial Regenerative Cells (ERC) Stem Cells in …

Page 6,247«..1020..6,2466,2476,2486,249..6,2606,270..»